# A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

> **NCT05809934** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 220 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** AZD2693
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05809934
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-15
- **Primary completion:** 2025-07-14
- **Final completion:** 2025-09-29
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809934, "A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05809934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*